Patents by Inventor Andrew John Harvey

Andrew John Harvey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210196734
    Abstract: The present disclosure relates to compounds of formula I that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation
    Type: Application
    Filed: March 5, 2021
    Publication date: July 1, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Brendan M. Crowley, Ian M. Bell, Andrew John Harvey, Brian T. Campbell, Thomas J. Greshock, Vanessa L. Rada
  • Patent number: 11026958
    Abstract: The present disclosure relates to compounds of formula (I) that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: June 8, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Brendan M. Crowley, Ian M. Bell, Andrew John Harvey, Brian T. Campbell, Thomas J. Greshock, Vanessa L. Rada
  • Publication number: 20210077511
    Abstract: present disclosure relates to compounds of formula (I) that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.
    Type: Application
    Filed: October 30, 2017
    Publication date: March 18, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: BRENDAN M. CROWLEY, IAN M. BELL, ANDREW JOHN HARVEY, BRIAN T. CAMPBELL, THOMAS J. GRESHOCK, VANESSA L. RADA
  • Patent number: 10870630
    Abstract: The present disclosure relates to compounds of formula (I) that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: December 22, 2020
    Inventors: Brendan M. Crowley, Ian M. Bell, Andrew John Harvey, William D. Shipe, Kenneth J. Leavitt, John M. Sanders, Deodial G. Guiadeen, Linda M. Suen, Thomas J. Greshock, Vanessa L. Rada
  • Publication number: 20190337910
    Abstract: The present disclosure relates to compounds of formula (I) that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.
    Type: Application
    Filed: March 20, 2017
    Publication date: November 7, 2019
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: BRENDAN M. CROWLEY, BRIAN T. CAMPBELL, JOSEPH L. DUFFY, THOMAS J. GRESHOCK, DEODIAL G. GUIADEEN, ANDREW JOHN HARVEY, BELINDA C. HUFF, KENNETH J. LEAVITT, VANESSA L. RADA, JOHN M. SANDERS, WILLIAM D. SHIPE, LINDA M. SUEN, IAN M. BELL
  • Publication number: 20190308945
    Abstract: The present disclosure relates to compounds of formula (I) that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.
    Type: Application
    Filed: October 30, 2017
    Publication date: October 10, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: BRENDAN M. CROWLEY, IAN M. BELL, ANDREW JOHN HARVEY, WILLIAM D. SHIPE, KENNETH J. LEAVITT, JOHN M. SANDERS, DEODIAL GUY GUIADEEN, LINDA M. SUEN, THOMAS J. GRESHOCK, VANESSA L. RADA
  • Patent number: 10266529
    Abstract: The present invention provides crystalline Forms FUM-P3, FUM-P4, MLA-P3 and MLA-P4 of compound formula 1 and related methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using a crystalline Form FUM-P3, FUM-P4, MLA-P3 and MLA-P4 of compound formula 1 and/or pharmaceutical compositions thereof.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: April 23, 2019
    Assignees: Bionomics Limited, Ironwood Pharmaceuticals, Inc.
    Inventors: Bernard Luke Flynn, Dharam Paul, Andrew John Harvey, Vasu V. Sethuraman, Raymond E. Forslund, Song Xue, Rob Livingston, Ahmad Hashash
  • Patent number: 9926285
    Abstract: The present disclosure relates to compounds of formula I that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: March 27, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Brendan M. Crowley, Brian T. Campbell, Joseph L. Duffy, Andrew John Harvey, Ian M. Bell
  • Publication number: 20180030007
    Abstract: The present disclosure relates to compounds of formula I that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation
    Type: Application
    Filed: October 9, 2017
    Publication date: February 1, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Brendan M. Crowley, Brian T. Campbell, Joseph L. Duffy, Thomas J. Greshock, Deodial G. Guiadeen, Andrew John Harvey, Belinda C. Huff, Kenneth J. Leavitt, Vanessa L. Rada, John M. Sanders, William D. Shipe, Linda M. Suen, Ian M. Bell
  • Publication number: 20170362230
    Abstract: The present invention provides crystalline Forms FUM-P3, FUM-P4, MLA-P3 and MLA-P4 of compound formula 1 and related methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using a crystalline Form FUM-P3, FUM-P4, MLA-P3 and MLA-P4 of compound formula 1 and/or pharmaceutical compositions thereof.
    Type: Application
    Filed: August 25, 2017
    Publication date: December 21, 2017
    Inventors: Bernard Luke FLYNN, Dharam PAUL, Andrew John HARVEY, Vasu V. SETHURAMAN, Raymond E. FORSLUND, Song XUE, Rob LIVINGSTON, Ahmad HASHASH
  • Patent number: 9840481
    Abstract: The present disclosure relates to compounds of formula I that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: December 12, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Brendan M. Crowley, Brian T. Campbell, Joseph L. Duffy, Thomas J. Greshock, Deodial G. Guiadeen, Andrew John Harvey, Belinda C. Huff, Kenneth J. Leavitt, Vanessa L. Rada, John M. Sanders, William D. Shipe, Linda M. Suen, Ian M. Bell
  • Publication number: 20170305905
    Abstract: The present invention provides a crystalline Form B of compound 1, and pharmaceutically compositions thereof. The present invention also provides methods of treating a disease (e.g., a disease of the central nervous system) using the pharmaceutical compositions.
    Type: Application
    Filed: June 29, 2017
    Publication date: October 26, 2017
    Inventors: Bernard Luke Flynn, Dharam Paul, Andrew John Harvey
  • Publication number: 20170275260
    Abstract: The present disclosure relates to compounds of formula I that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation
    Type: Application
    Filed: March 20, 2017
    Publication date: September 28, 2017
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: BRENDAN M. CROWLEY, BRIAN T. CAMPBELL, JOSEPH L. DUFFY, THOMAS J. GRESHOCK, DEODIAL G. GUIADEEN, ANDREW JOHN HARVEY, BELINDA C. HUFF, KENNETH J. LEAVITT, VANESSA L. RADA, JOHN M. SANDERS, WILLIAM D. SHIPE, LINDA M. SUEN, IAN M. BELL
  • Patent number: 9758516
    Abstract: A crystalline Form B of compound 1 can be used in pharmaceutically compositions. The pharmaceutical compositions can be used in methods of treating a disease (e.g., a disease of the central nervous system).
    Type: Grant
    Filed: May 14, 2013
    Date of Patent: September 12, 2017
    Assignee: BIONOMICS LIMITED
    Inventors: Bernard Luke Flynn, Dharam Paul, Andrew John Harvey
  • Patent number: 9745296
    Abstract: The present invention provides amorphous arid crystalline forms of 1-ethyl-6-(indan-2-ylamino)-3-(morpholine-4-carbonyl)-1,8-naphthyridin-4-one (compound 1), and salts, co-crystals, and pharmaceutical compositions thereof. The invention also provides methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using the amorphous and crystalline forms, and salts, co-crystals, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 29, 2017
    Assignees: BIONOMICS LIMITED, IRONWOOD PHARMACEUTICALS, INC.
    Inventors: Bernard Luke Flynn, Dharam Paul, Andrew John Harvey, Vasu V. Sethuraman, Raymond E. Forslund, Song Xue, Rob Livingston, Ahmad Hashash
  • Publication number: 20160185770
    Abstract: The present invention provides amorphous arid crystalline forms of 1-ethyl-6-(indan-2-ylamino)-3-(morpholine-4-carbonyl)-1,8-naphthyridin-4-one (compound 1), and salts, co-crystals, and pharmaceutical compositions thereof. The invention also provides methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using the amorphous and crystalline forms, and salts, co-crystals, and pharmaceutical compositions thereof.
    Type: Application
    Filed: March 14, 2014
    Publication date: June 30, 2016
    Inventors: Bernard Luke FLYNN, Dharam PAUL, Andrew John HARVEY, Vasu V. SETHURAMAN, Raymond E. FORSLUND, Song XUE, Rob LIVINGSTON, Ahmad HASHASH
  • Patent number: 9266864
    Abstract: This invention relates to compounds of the formula (I): The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for the treatment of proliferative diseases, such as cancer, as well as the treatment of diseases ameliorated by the control and/or inhibition of lymphangiogenesis.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: February 23, 2016
    Assignee: CANCER THERAPEUTICS CRC PTY LIMITED
    Inventors: Richard Charles Foitzik, Neil Choi, Benjamin Joseph Morrow, Catherine Fae Hemley, Gillian Elizabeth Lunniss, Michelle Ang Camerino, Danny Ganame, Paul Anthony Stupple, Romina Lessene, Wilhelmus Johannes Antonius Kersten, Andrew John Harvey, Ian Peter Holmes
  • Publication number: 20160039810
    Abstract: A crystalline Form B of compound 1 can be used in pharmaceutically compositions. The pharmaceutical compositions can be used in methods of treating a disease (e.g., a disease of the central nervous system).
    Type: Application
    Filed: May 14, 2013
    Publication date: February 11, 2016
    Applicant: Bionomics Limited
    Inventors: Bernard Luke FLYNN, Dharam PAUL, Andrew John HARVEY
  • Patent number: 9238644
    Abstract: This invention relates to a compound of the formula (I): The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for the treatment of proliferative diseases, such as cancer, as well as the treatment of diseases ameliorated by the control and/or inhibition of lymphangiogenesis.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: January 19, 2016
    Assignee: CANCER THERAPEUTICS CRC PTY LIMITED
    Inventors: Richard Charles Foitzik, Benjamin Joseph Morrow, Catherine Fae Hemley, Gillian Elizabeth Lunniss, Michelle Ang Camerino, Danny Ganame, Paul Anthony Stupple, Romina Lessene, Wilhelmus Johannes Antonius Kersten, Andrew John Harvey, Ian Peter Holmes
  • Publication number: 20160009686
    Abstract: This invention relates to a compound of the formula (I): The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for the treatment of proliferative diseases, such as cancer, as well as the treatment of diseases ameliorated by the control and/or inhibition of lymphangiogenesis.
    Type: Application
    Filed: August 16, 2013
    Publication date: January 14, 2016
    Applicant: CANCER THERAPEUTICS CRC PTY LIMITED
    Inventors: Richard Charles Foitzik, Benjamin Joseph Morrow, Catherine Fae Hemley, Gillian Elizabeth Lunniss, Michelle Ang Camerino, Danny Ganame, Paul Anthony Stupple, Romina Lessene, Wilhelmus Johannes Antonius Kersten, Andrew John Harvey, Ian Peter Holmes